Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study

NCT02342145 is registered in ClinicalTrials.gov with Zhongming Zhang as lead sponsor.

NCT NCT02342145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02342145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study
Lead sponsor
Zhongming Zhang
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2015
Completion date
August 20, 2022
Enrollment
205 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia major, graft-versus-host disease (gvhd)